-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa Therapeutics Plans Phase 2 Gout Trial of MRT-8102 in Q4 2026

PUBT·11/09/2026 12:02:38
Listen to the news
Monte Rosa Therapeutics Plans Phase 2 Gout Trial of MRT-8102 in Q4 2026
  • Monte Rosa Therapeutics expects to start GEMINI-1, a Phase 2 trial of MRT-8102 in gout patients, in the fourth quarter of 2026.
  • The trial will evaluate prevention of recurrent flares following acute treatment, with initial data expected in the second half of 2027.
  • Preclinical results showed reduced joint swelling in rabbits with gouty arthritis and suppressed inflammatory activity in human experimental systems.
  • These findings will be presented at ACR Convergence on November 9, 2026, supporting the planned clinical evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872774) on November 09, 2026, and is solely responsible for the information contained therein.